FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /

6/22/2021 9:41:54 PM	Chg. +0.620	Volume	Bid9:58:01 PM	Ask9:58:01 PM	Market Capitalization	Dividend Y.	P/E Ratio
44.545EUR	+1.41%	31,192 Turnover: 1.38 mill.	44.500Bid Size: 9,572	44.600Ask Size: 1,500	24.7 bill.EUR	1.99%	14.48

GlobeNewswire 3:00 PM Integrity Applications Appoints Luis J. Malavé to Board of Directors

GlobeNewswire 6/11 Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

GlobeNewswire 11/11/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 11/7/2019 eGenesis Announces $100 Million Series B Financing

GlobeNewswire 11/4/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/29/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/23/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...

TeleTrader 8/7/2017 Fresenius Medical buys NxStage for $2 billion

GlobeNewswire 7/19/2017 Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi

GlobeNewswire 6/9/2017 KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

GlobeNewswire 4/7/2017 Akorn Confirms Discussions with Fresenius Kabi

GlobeNewswire 1/27/2011 Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®